The Food and Drug Administration (FDA) has reported that Hexabrix (ioxaglate meglumine, ioxaglate sodium; Guerbet LLC), a medical imaging agent.
Hexabrix is a radiopaque contrast medium indicated for use in pediatric angiocardiography, selective coronary arteriography with or without left ventriculography, peripheral arteriography, aortography, selective visceral arteriography, cerebral angiography, intra-arterial digital subtraction angiography, IV digital subtraction angiography, peripheral venography (phlebography), excretory urography, contrast enhancement of computed tomographic head imaging and body imaging, arthrography and hysterosalpingography.
RELATED: Evidence of Cellular Damage From CT Scans
Guerbet LLC has made a business decision to discontinue manufacturing of the following packages:
- 10x20mL vials (NDC 0019-5505-51)
- 25x50mL vials (NDC 67684-5505-2 or 0019-5505-06)
- 12x100mL fill/150mL bottle (NDC 67684-5505-3 or 0019-5505-08)
- 12x200mL fill/250mL bottle (NDC 67684-5505-5 or 0019-550-21)
For more information call (877) 729-6679 or visit FDA.gov.
